Patients with unresectable stage IIIC/IV BRAF V600E/K mutant melanoma were randomized to treatment with atezolizumab, vemurafenib and cobimetinib or placebo, vemurafenib and cobimetinib (15). This evidence concerns the gene BRAF and melanoma.